Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer - The ABCs of ADCs (Antibody drug Conjugates)

J Martin; E Zacholski; R O'Cearbhaill; U Matulonis; L Chen

doi:10.1016/j.gore.2023.101141

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer - The ABCs of ADCs (Antibody drug Conjugates)

Gynecol Oncol Rep. 2023 Feb 2:45:101141. doi: 10.1016/j.gore.2023.101141. eCollection 2023 Feb.

Authors

J Martin¹, E Zacholski², R O'Cearbhaill³, U Matulonis⁴, L Chen⁵

Affiliations

¹ Women's Cancer Care Associates, Albany, NY, United States.
² Virginia Commonwealth University, Richmond, VA, United States.
³ Memorial Sloan Kettering Cancer Center, New York, NY, United States.
⁴ Dana-Farber Cancer Institute, Boston, MA, United States.
⁵ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States.

Abstract

The Society of Gynecologic Oncology (SGO) Journal Club is held quarterly to discuss topics related to gynecological malignancies. On November 8, 2022, the SGO Journal Club focused on antibody-drug conjugates (ADCs) in gynecologic malignancies, including the pharmacology, toxicities, and results of recent clinical trials leading to FDA approval of two new therapies for cervical and ovarian cancer. The invited discussants included Drs. Erin Hickey Zacholski, Roisin O'Cearbhaill, and Ursula Matulonis who discussed the pharmacology of ADCs, GOG-3023/ENGOT-cx6 (Coleman et al., 2021 May) and the SORAYA study (Ursula Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert Coleman, Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4), Gynecologic Oncology, Volume 166, Supplement 1, ,2022).